Gluten intolerance disrupts daily life, sparking caution over every ingredient and limiting restaurant visits. A groundbreaking pill in development by researchers at the University of Alberta, Canada, could transform this reality. Crafted from egg yolk antibodies, it targets the estimated 600,000 individuals with celiac disease—about 0.3 to 1% of the population—who suffer true gluten intolerance.
Straightforward to use, the pill is taken just 5 minutes before a meal, providing 1-2 hours of protection—ideal for a full restaurant dinner. The antibodies bind to gluten in wheat, neutralizing it to ease hallmark symptoms: stomach pain, bloating, diarrhea, and impaired nutrient absorption. Lead researcher Hoon Sunwoo stresses it's designed for those with confirmed intolerance, distinct from gluten sensitivity.
While efficacy trials continue, this remains a temporary aid, not a cure for the incurable celiac disease. European testing is still pending, requiring patience from those affected.
